Archive


Category: Aldeyra

  • Aldeyra builds case for troubled dry eye drug reproxalap

    Prospects for Aldeyra’s dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn’t giving up, and has new data showing an improvement over Novartis rival therapy Xiidra. Patients treated with reproxalap reported significantly less eye discomfort and itching […]